Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company that offers innovative gastroenterology treatments.
PRESS RELEASE
LAVAL, Quebec
,
April 1, 2015
/PRNewswire/ --
Valeant Pharmaceuticals International, Inc.
(NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of
Salix Pharmaceuticals, Ltd.
Salix Pharmaceuticals
is a specialty pharmaceutical company that offers innovative gastroenterology treatments such as XIFAXAN® (rifaximin) 550 mg, RUCONEST® (C1 esterase inhibitor [recombinant]), APRISO® (mesalamine), UCERIS® (budesonide) extended release tablets and RELISTOR® (methylnaltrexone bromide).
About
Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc.
(NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about
Valeant Pharmaceuticals International, Inc.
can be found at www.valeant.com.
